SARS-CoV-2 rS - Phase 1

Phase 2Protein / enzyme

NNovavax

SARS-CoV-2 rS - Phase 1 is one of 43 biologic programs targeting COVID-19. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

InfluenzaActive, not recruiting

COVID-19Phase 2

Active, not recruiting

InfluenzaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Biaxin

AbbVie

Preclinical

2 2

Stivarga

Bayer

Preclinical

1 3

Singulair

AstraZeneca

Preclinical

1 4

SARS-CoV-2 rS - Phase 1

NNovavax

Phase 2

4 5

Nitrostat

VViatris Specialty LLC

Preclinical

1 6

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

—7

Biological Data

UUniversity Hospital, Bordeaux

Preclinical

3 8

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 9

Blood Taken

HHospices Civils de Lyon

Preclinical

1 10

Tpa

UUniversity of Florida

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-194 trials

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

Completed·NNovavax·Phase 3·NCT04611802·33,000 enrolled

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

Active, not recruiting·NNovavax·Phase 2/3·NCT05468736·3,600 enrolled

A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults

Completed·NNovavax·Phase 2·NCT04533399·4,422 enrolled

Show 1 more trial

A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom

Completed·NNovavax·Phase 3·NCT04583995·15,185 enrolled

Influenza1 trial

A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine

Completed·NNovavax·Phase 2·NCT05519839·1,579 enrolled

mRNA Vaccine1 trial

Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines

Completed·NNovavax·Phase 3·NCT05875701·147 enrolled

Immunogenicity1 trial

Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant

Completed·NNovavax·Phase 1/2·NCT04368988·1,419 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for SARS-CoV-2 rS - Phase 1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SARS-CoV-2 rS - Phase 1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SARS-CoV-2 rS - Phase 1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novavax company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: NNovavax

SARS-CoV-2 rS - Phase 1

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

COVID-194 trials

Influenza1 trial

mRNA Vaccine1 trial

Immunogenicity1 trial

References

Drug Info

Quick Facts

Related News